Interestingly, the inclusion of exogenous Bcl-xL gene into a second-generation anti-CEA CAR retroviral construct promoted CAR T-cell persistence both in vitro and in vivo, with enhanced antitumor potency and sustained survival in a CRC mouse model. Here, CEACAM5 is linked to colorectal carcinoma.